U.S. Markets open in 3 hrs 47 mins

Biotech Stocks on the Rise

HENDERSON, NV / ACCESSWIRE / January 31, 2019 / With the IBB getting set to cap off its most bullish month in a while, the biotech industry could be in store for a major renaissance in 2019. Below are a few biotech companies you will want to know about.

An oversold biotech with huge upside potential we really like is Delcath Systems, Inc. (DCTH). Last September, the stock reached highs above $8, and is now sitting around support at $0.26. With promising liver cancer treatments in development (phase 3 clinical trials), increased revenue this past year, and a new licensing deal with a projected value of up to $45 million, there is a lot for potential investors to be excited about. With not much awareness among investors yet, it has not reached a proper market valuation, and that's why we think you should start researching DCTH today.

Today we are highlighting: Delcath Systems, Inc. (DCTH), Histogenix Corporation (HSGX), Generex Biotechnology Corporation (GNBT), Corbus Pharmaceutical Holdings, Inc. (NASDAQ: CRBP), and Geron Corporation (GERN).

An interventional oncology company focused on treating liver cancers with major upside potential, Delcath Systems, Inc. (DCTH)(Market Cap: $3.126M, Share Price: $0.28), has had quite a year. They announced an amendment to their ongoing Phase 3 clinical trial, raised $7 million, increased revenue 20% Y/Y, and were published in European Radiology among several other milestones.

DCTH made big news recently entering a licensing agreement for CHEMOSAT® commercialization in Europe with medac Gesellschaft für klinische Spezialpräparate mbH (medac). The agreement has a projected value of up to $45 million over the first seven-year term and includes an optional five-year extension. Medac is a privately held, multi-national pharmaceutical company based in Hamburg area, Germany. Founded in 1970, Medac specializes in the treatment and diagnosis of oncological, urological and autoimmune diseases. The company has offices globally, worldwide partner agreements in over 90 countries, and approximately 1,200 employees.

The Company anticipates to be able to complete enrollment in its Phase 3 ocular melanoma trial this year, so there is upside potential and this is why we think the company could be part of a biotech rally. Research DCTH now.


Histogenix Corporation (HSGX) (Market Cap: $8.56M, Share Price: $0.1380) reported an update on their NeoCart regulatory pathway based on discussions with the FDA indicating that an additional trial would need to be completed before it would accept submission of a Biologics License Application for NeoCart.


Generex Biotechnology Corporation (GNBT) (Market Cap: $147.712M, Share Price: $2.45) announced today that its wholly-owned subsidiary NuGenerex Distribution Solutions 2, LLC (NDS) has launched DME-IQ, a novel service for physicians who manage in-office distribution of durable medical equipment (DME). DME-IQ supports the development and management of compliant and profitable in-office DME programs.


Corbus Pharmaceutical Holdings, Inc. (CRBP) (Market Cap: $413.327M, Share Price: $7.22), a clinical stage drug development company with the industry's leading pipeline focused on treating inflammatory and fibrotic diseases through the endocannabinoid system pathways, announced the pricing of an underwritten public offering of 5,390,000 shares of its common stock at a public offering price of $6.50 per share, for a total public offering size of approximately $35 million.


Geron Corporation (GERN) (Market Cap: $191.938M, Share Price: $1.03) announced the hiring of the first of several key leadership positions as it rebuilds the in-house development team to support its plans to initiate a Phase 3 clinical trial of imetelstat in lower risk myelodysplastic syndromes by mid-year 2019.

Legal Disclaimer:

This article was written by Regal Consulting, LLC (''Regal Consulting''). Regal Consulting has agreed to a twelve-month term consulting agreement with DCTH dated 8/31/18. The agreement calls for $40,000 in cash, and 15,000 restricted 144 shares of DCTH per month. Issuer agreed to increase monthly cash payment in September to $120,000. All payments were made directly by Delcath Systems, Inc. to Regal Consulting, LLC. to provide investor relations services, of which this article is a part of. Regal Consulting also paid one thousand dollars cash to microcapspecultors.com to distribute this article. Regal Consulting may have a position in the securities mentioned in this article at the time of publication, and may increase or decrease its position without notice. This article is based on public information and the opinions of Regal Consulting. DCTH was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein. Regal Consulting is not registered with any financial or securities regulatory authority, and does not provide or claim to provide investment advice.

http://www.regalconsultingllc.com/full legal disclaimer/

Microspeculators.com Full Legal Disclaimer Click Here.


Company Name: Microcap Speculators

Contact Person: Media Manager

Email: info@microcapspeculators.com

Phone: 1-702-720-6310

Country: United States

Website: http://microcapspeculators.com/

SOURCE: ACR Communication, LLC